265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details


臨床試験数 : 116 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00192660
(ClinicalTrials.gov)
February 200312/9/2005HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First TimeHIV-Associated Lipodystrophy Syndrome;Cardiovascular DiseaseDrug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/ABoth80Phase 4Australia
2NCT00457665
(ClinicalTrials.gov)
February 20024/4/2007Mechanisms of Lipodystrophy in HIV-Infected PateintsMecahnisms of Lipodystrophy in HIV-Infected PatientsHIV InfectionsDrug: Nelfinavir;Drug: EfavirenzUniversity of Texas Southwestern Medical CenterBristol-Myers Squibb;GlaxoSmithKlineCompleted18 Years70 YearsAll56Phase 4United States
3NCT00017758
(ClinicalTrials.gov)
June 200111/6/2001The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering DrugsThe Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase InhibitorsHIV Infections;HIV Seronegativity;LipodystrophyDrug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: EfavirenzNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years60 YearsBoth56Phase 1United States
4NCT00006190
(ClinicalTrials.gov)
November 200025/8/2000A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop LipodystrophyThe Study of Mechanisms of Lipodystrophy in HIV-Infected PatientsHIV Infections;LipodystrophyDrug: Nelfinavir mesylate;Drug: Stavudine;Drug: Lamivudine;Drug: EfavirenzNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 Years70 YearsBothPhase 4United States